Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety
Cancers · 17.03.2023 · 15 (6) · 1819
DOI: 10.3390/cancers15061819 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.03.2023. Verfasst von Dawn Swan und 3 weiteren Autor:innen. Beteiligte Einrichtung: RCSI Beaumont Cancer Centre, D09V2N0 Dublin, Ireland. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) is the second most common haematological neoplasm of adults in the Western world. Overall survival has doubled since the advent of proteosome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. However, patients with adverse cytogenetics or high-risk disease as determined by the Revised International Staging System (R-ISS) continue to have poorer outcomes, and triple-refractory patients have a median survival of less than 1 year. Bispecific antibodies (BsAbs) commonly bind to a tumour epitope along with CD3 on T-cells, leading to T-cell activation and tumour cell killing. These treatments show great promise in MM patients, with the first agent, teclistamab, receiving regulatory approval in 2022. Their potential utility is hampered by the immunosuppressive tumour microenvironment (TME), a hallmark of MM, which may limit efficacy, and by undesirable adverse events, including cytokine release syndrome (CRS) and infections, some of which may be fatal. In this review, we first consider the means of enhancing the efficacy of BsAbs in MM. These include combining BsAbs with other drugs that ameliorate the effect of the immunosuppressive TME, improving target availability, the use of BsAbs directed against multiple target antigens, and the optimal time in the treatment pathway to employ BsAbs. We then discuss methods to improve safety, focusing on reducing infection rates associated with treatment-induced hypogammaglobulinaemia, and decreasing the frequency and severity of CRS. BsAbs offer a highly-active therapeutic option in MM. Improving the efficacy and safety profiles of these agents may enable more patients to benefit from these novel therapies and improve outcomes for patients with high-risk disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- RCSI Beaumont Cancer Centre, D09V2N0 Dublin, Ireland.
ORCID-Profile: Dawn Swan
Zitieren
APA
Swan, D., Murphy, P., Glavey, S., & Quinn, J. (2023). Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Cancers, 15(6), 1819. https://doi.org/10.3390/cancers15061819
Vancouver
Swan D, Murphy P, Glavey S, Quinn J. Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Cancers. 2023;15(6):1819. doi:10.3390/cancers15061819
BibTeX
@article{Swan2023,
author = {Swan, Dawn and Murphy, Philip and Glavey, Siobhan and Quinn, John},
title = {Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety},
journal = {Cancers},
year = {2023},
volume = {15},
number = {6},
pages = {1819},
doi = {10.3390/cancers15061819}
}
EUVIMED